On January 6, 2026, Alpha Tau Medical Ltd. announced new positive results related to its Alpha DaRT® study for pancreatic cancer, set to be presented at the ASCO GI 2026 Symposium. The event is significant as it showcases the company's advancements in immune preservation and disease control.